Back to Search Start Over

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression

Authors :
Booil Jo
Austin T Guerra
John P. Coetzee
Heather Pankow
Brandon S. Bentzley
Fahim Barmak
E. Cole
Kristin S. Raj
Alan F. Schatzberg
James Bishop
Flint M. Espil
Charles DeBattista
Jaspreet Pannu
Jennifer Keller
Dalton Duvio
Xiaoqian Xiao
Nolan R. Williams
M. Gulser
Jessica Hawkins
Hugh B. Solvason
Katy H. Stimpson
Romina Nejad
Angela Phillips
Claudia Tischler
Haley Aaron
Keith Sudheimer
Elizabeth Choi
Kirsten Cherian
Source :
American Journal of Psychiatry. 177:716-726
Publication Year :
2020
Publisher :
American Psychiatric Association Publishing, 2020.

Abstract

New antidepressant treatments are needed that are effective, rapid acting, safe, and tolerable. Intermittent theta-burst stimulation (iTBS) is a noninvasive brain stimulation treatment that has been approved by the U.S. Food and Drug Administration for treatment-resistant depression. Recent methodological advances suggest that the current iTBS protocol might be improved through 1) treating patients with multiple sessions per day at optimally spaced intervals, 2) applying a higher overall pulse dose of stimulation, and 3) precision targeting of the left dorsolateral prefrontal cortex (DLPFC) to subgenual anterior cingulate cortex (sgACC) circuit. The authors examined the feasibility, tolerability, and preliminary efficacy of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), an accelerated, high-dose resting-state functional connectivity MRI (fcMRI)-guided iTBS protocol for treatment-resistant depression.Twenty-two participants with treatment-resistant depression received open-label SAINT. fcMRI was used to individually target the region of the left DLPFC most anticorrelated with sgACC in each participant. Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) were delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold (adjusted for cortical depth). Neuropsychological testing was conducted before and after SAINT.One participant withdrew, leaving a sample size of 21. Nineteen of 21 participants (90.5%) met remission criteria (defined as a score11 on the Montgomery-Åsberg Depression Rating Scale). In the intent-to-treat analysis, 19 of 22 participants (86.4%) met remission criteria. Neuropsychological testing demonstrated no negative cognitive side effects.SAINT, an accelerated, high-dose, iTBS protocol with fcMRI-guided targeting, was well tolerated and safe. Double-blinded sham-controlled trials are needed to confirm the remission rate observed in this initial study.

Details

ISSN :
15357228 and 0002953X
Volume :
177
Database :
OpenAIRE
Journal :
American Journal of Psychiatry
Accession number :
edsair.doi.dedup.....4ccdfd7bc61b12692cac2f1eca3c1cd5
Full Text :
https://doi.org/10.1176/appi.ajp.2019.19070720